Karuna Therapeutics, Inc. (KRTX) has a consensus analyst rating of Buy, based on 25 analysts covering the stock. Of those, 16 recommend buying, 9 recommend holding, and 0 recommend selling.
The analyst consensus price target for KRTX is $257.50, representing a -21.9% downside from the current price of $329.83. Price targets range from a low of $150.00 to a high of $330.00.
